Show simple item record

Therapeutic evolution in HR+/HER2- breast cancer: from targeted therapy to endocrine therapy

dc.contributor.authorLu-Qi Cao
dc.contributor.authorLu-Qi Cao
dc.contributor.authorHaidong Sun
dc.contributor.authorYuhao Xie
dc.contributor.authorHarsh Patel
dc.contributor.authorLetao Bo
dc.contributor.authorHanli Lin
dc.contributor.authorZhe-Sheng Chen
dc.contributor.authorZhe-Sheng Chen
dc.contributor.otherInstitute for Biotechnology, St. John’s University, Queens, NY, United States
dc.contributor.otherDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, Queens, NY, United States
dc.contributor.otherShenzhen Hospital (Futian) of Guangzhou University of Chinese Medicine, Shenzhen, China
dc.contributor.otherDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, Queens, NY, United States
dc.contributor.otherDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, Queens, NY, United States
dc.contributor.otherDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, Queens, NY, United States
dc.contributor.otherShenzhen Hospital (Futian) of Guangzhou University of Chinese Medicine, Shenzhen, China
dc.contributor.otherInstitute for Biotechnology, St. John’s University, Queens, NY, United States
dc.contributor.otherDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, Queens, NY, United States
dc.date.accessioned2024-01-24T04:11:31Z
dc.date.accessioned2025-10-08T08:56:53Z
dc.date.available2025-10-08T08:56:53Z
dc.date.issued01-01-2024
dc.identifier.urihttp://digilib.fisipol.ugm.ac.id/repo/handle/15717717/38304
dc.description.abstractBreast cancer, a complex and varied disease, has four distinct subtypes based on estrogen receptor and human epidermal growth factor receptor 2 (HER2) levels, among which a significant subtype known as HR+/HER2-breast cancer that has spurred numerous research. The prevalence of breast cancer and breast cancer-related death are the most serious threats to women’s health worldwide. Current progress in treatment strategies for HR+/HER2-breast cancer encompasses targeted therapy, endocrine therapy, genomic immunotherapy, and supplementing traditional methods like surgical resection and radiotherapy. This review article summarizes the current epidemiology of HR+/HER2-breast cancer, introduces the classification of HR+/HER2-breast cancer and the commonly used treatment methods. The mechanisms of action of various drugs, including targeted therapy drugs and endocrine hormone therapy drugs, and their potential synergistic effects are deeply discussed. In addition, clinical trials of these drugs that have been completed or are still in progress are included.
dc.language.isoEN
dc.publisherFrontiers Media S.A.
dc.subject.lccTherapeutics. Pharmacology
dc.titleTherapeutic evolution in HR+/HER2- breast cancer: from targeted therapy to endocrine therapy
dc.typeArticle
dc.description.keywordsHR+/HER2-breast cancer
dc.description.keywordsclinical trial
dc.description.keywordsCDK4/6 inhibitor
dc.description.keywordsPI3K inhibitor
dc.description.keywordsSERM
dc.description.keywordsSERD
dc.description.doi10.3389/fphar.2024.1340764
dc.title.journalFrontiers in Pharmacology
dc.identifier.e-issn1663-9812
dc.identifier.oaioai:doaj.org/journal:d3127d7745a84800b18e83e0236fc44b


This item appears in the following Collection(s)

Show simple item record